65938-88-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinesulfonamide is used as a key intermediate in the synthesis of sulfa drugs, which are a group of antibiotics containing sulfonamides. These drugs are effective against a wide range of bacterial infections and have been widely used in the treatment of various diseases.
Used in Chemical Reactions:
4-Pyridinesulfonamide is used as a reactant in various chemical reactions due to its unique properties and composition. Its presence in the synthesis of sulfa drugs highlights its importance in the development of new pharmaceutical compounds and its potential applications in medicinal chemistry.

InChI:InChI=1/C5H6N2O2S/c6-10(8,9)5-1-3-7-4-2-5/h1-4H,(H2,6,8,9)

Upstream product

• 19829-29-9 4-pyridinethione 
• 4556-23-4 pyridine-4-thiol 
• 7647-01-0 hydrogenchloride 
• 7782-50-5 chlorine 
• 134479-04-2 pyridine-4-sulfonyl chloride 
• 2645-22-9 dipyridin-4-yl disulfide 

Downstream Products

• 75903-65-0 pyridine-4-sulfonamide N-oxide 
• 1585225-15-5 3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-N-(pyridin-4-ylsulfonyl)-1H-indole-2-carboxamide 

Relevant academic research and scientific papers

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

Crystal structures of pyridine sulfonamides and sulfonic acids

Despite the widespread occurrence of pyridinesulfonic acid and pyridinesulfonamide functional groups in drugs and pharmaceuticals, and their use as ligands in metal-organic frameworks, a systematic structural study of their hydrogen bonding and molecular packing is lacking. We discuss crystal structures of 2-, 3-, and 4-pyridinesulfonic acids/amides in terms of N +-H???O- hydrogen bonds, N-H???O dimer/catemer synthons, and graph set notations. This model study provides a background for polymorph screening and solid form hunting of pharmacologically active sulfonamides.

From haloquinolines and halopyridines to quinoline- and pyridinesulfonyl chlorides and sulfonamides

The action of sodium methanethiolate (in boiling DMF) towards haloazines (i.e. chloro- or bromo-pyridines and quinolines) (1) (with halogen substituent in non-aza-activated position) causes sequentially halogen ipso-substitution to methylthioazines (2) and then S-demethylation to azinethiolates (3A), which were: i) subjected to S-methylation, ii) oxidized to diazinyl disulfides (4) and iii) oxidatively chlorinated to azinesulfonyl chlorides (5). α- and γ-pyridine- and quinolinesulfonyl chlorides (5a, 5c, 5d and 5f) were prepared by oxidative chlorination of respective disulfides (4) performed in conc. hydrochloric acid and characterized by 1H and 13C NMR spectra. All azinesulfonyl chlorides (5) were effectively converted to corresponding azinesulfonamides (6).

PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.

PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS

The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R 10 and R 20 taken together are formulae (III) and (IV). STR1